Elixiron Immunotherapeutics

Public

Elixiron Immunotherapeutics is now publicly traded

The data on this page reflects Elixiron Immunotherapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Series B

Jun 12, 2025

Total Funding Raised

$70M

Company Overview

Elixiron Immunotherapeutics has raised $70M. It was founded in 2017.

Elixiron Immunotherapeutics is a clinical-stage biotechnology company that develops precision immunotherapies for neuroinflammatory diseases, autoimmune diseases, and cancer.

AI Layer

Application

Elixiron Immunotherapeutics Comparables

Compare Elixiron Immunotherapeutics with similar companies based on industry and business-model similarity.

Elixiron Immunotherapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Pilatus Biosciences	73%	Demo
SynOx Therapeutics	57%	Demo

Book a demo to see all comparables

For institutional investors. Book with your work email.

Elixiron Immunotherapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Jun 12, 2025	Demo	Demo	Demo	Demo
Grant	Jul 12, 2022	Demo	Demo	Demo	Demo
Series A Extension	Aug 23, 2021	Demo	Demo	Demo	Demo
Grant	Aug 25, 2020	Demo	Demo	Demo	Demo
Series A	Jul 31, 2019	Demo	Demo	Demo	Demo

Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Cheng-Lung KU

Chief Science Officer, Co-Founder

Founding Team

For institutional investors. Book with your work email.

Elixiron Immunotherapeutics Investors

Notable investors and investment history

Elixiron Immunotherapeutics investors
Investor	Rounds
Taiwania Capital	Series A, Series A Extension
Fubon Financial Holding Venture Capital	Series A Extension
CDIB Capital International	Series A
China Investment & Development Company, Limited	Series A Extension
Alzheimer's Association	Grant
Fubon Financial Holdings	Series A Extension

Elixiron Immunotherapeutics Filings

Explore SEC and related filing metadata, where available.

Elixiron Immunotherapeutics filings preview — column headings only; records require access
Type	Date	Amount Offered	Amount Sold	Filing	Pages	Download

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Firmographic Details

Headquarters—

Employee Range17

Year Founded2017

Last FundingJun 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?